Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-08	US$0.3637	-2.49%	222,988
26-09-04	US$0.3730	+0.87%	142,606
26-09-03	US$0.3698	-0.05%	299,509
26-09-02	US$0.3700	+0.82%	120,769
26-09-01	US$0.3670	-5.53%	380,371

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3637USD

Average target price

1.500USD

Spread / Average Target

+312.43%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-09-08 EDT			5-day change	1st Jan Change
0.3637 ^USD	-2.49%		-0.90%	-28.69%

08-13	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI

Market Cap	14.94M 12.84M 12.08M 11.02M 20.57M 1.42B 20.68M 143M 55.38M 724M 56.08M 54.86M 2.3B	P/E 2026 *	-1.58x	P/E 2027 *	-
Enterprise Value	14.94M 12.84M 12.08M 11.02M 20.57M 1.42B 20.68M 143M 55.38M 724M 56.08M 54.86M 2.3B	EV / Sales 2026 *	3.12x	EV / Sales 2027 *	0.87x
Free-Float	86.83%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	SCNX	Delayed
CBOE	SCNX	Real-time
Deutsche Boerse AG	4E4	Delayed
Tradegate	4E4	Real-time

08-13	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI
07-09	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
06-18	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
06-09	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
06-02	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
05-29	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
05-29	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
05-15	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
05-07	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
04-26	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
03-30	Scienture reports year end 2025 financial results and provides business update	RE

Scienture Holdings, Inc. Stock

Stocks

SCNX

US80880X1046

Pharmaceuticals

Valuation : Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news : Scienture Holdings, Inc.

Last Transcript : Scienture Holdings, Inc.

Analysts' recommendations : Scienture Holdings, Inc.

Press Releases : Scienture Holdings, Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

25-08-14	Top Midday Decliners	MT
23-06-01	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
23-03-28	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
22-05-10	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
22-03-29	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

08-14	SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance	AQ
08-13	Scienture Holdings: Q2 Earnings Snapshot	AQ
08-12	SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray	AQ
07-09	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers	AQ
06-18	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide	AQ

1 day	-2.49%
1 week	-0.90%
Current month	-6.38%
1 month	-4.31%
3 months	+3.32%
6 months	-8.20%
Current year	-28.69%

1 week	0.36	0.38
1 month	0.35	0.48
Current year	0.24	0.64
1 year	0.24	2.6
3 years	0.24	13.42
5 years	0.24	13.42
10 years	0.24	13.42

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/19/24	Narasimhan Mani	Conversion	Director	2,927,538	-
9/19/24	Shankar Hariharan	Conversion	Chief Executive Officer	3,853,296	-
7/25/24	Narasimhan Mani	Other	Director	57,977	4.1225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	-2.49%	-0.90%	-59.09%	-	14.94M
MCKESSON CORPORATION	-2.08%	-1.95%	+27.57%	+111.30%	104B
CARDINAL HEALTH, INC.	-2.71%	+0.48%	+60.03%	+170.88%	55.93B
SIGMA HEALTHCARE LIMITED	-0.37%	-1.48%	-11.59%	+256.00%	22.26B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+0.12%	+1.10%	-10.19%	-6.17%	8.24B
HUADONG MEDICINE CO., LTD	+0.37%	-0.29%	-37.63%	-26.67%	7.13B
H. LUNDBECK A/S	-0.89%	-1.54%	+4.06%	+29.12%	6.76B
SINOPHARM GROUP CO. LTD.	-2.06%	+2.35%	-15.41%	-28.31%	6.38B
GALENICA AG	+0.75%	+0.66%	-3.84%	+21.21%	5.13B
SELÇUK ECZA DEPOSU TICARET VE SANAYI	+0.53%	+9.04%	+371.25%	+523.14%	4.81B
Average	-0.88%	+1.56%	+32.52%	+116.72%	22.03B
Weighted average by Cap.	-1.75%	+0.81%	+33.12%	+132.52%

	2026 *	2027 *
Net sales	4.79M 4.12M 3.87M 3.54M 6.6M 454M 6.63M 45.9M 17.76M 232M 17.98M 17.59M 738M	17.22M 14.8M 13.93M 12.71M 23.72M 1.63B 23.84M 165M 63.84M 834M 64.65M 63.24M 2.65B
Net income	-9.62M -8.27M -7.78M -7.1M -13.26M -912M -13.32M -92.22M -35.68M -466M -36.13M -35.34M -1.48B	135K 116K 109K 99.65K 186K 12.8M 187K 1.29M 501K 6.54M 507K 496K 20.82M
Net Debt	-	-